Axatilimab (Niktimvo)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

colony stimulating factor-1 receptor-blocking antibody

Diseases for which it is established

History of changes in FDA indication

  • 2024-08-14: Initial approval for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. (Based on AGAVE-201)

Also known as

  • Generic name: axatilimab-csfr
  • Brand name: Niktimvo